Gaudium IVF IPO allotment likely today; here's how to check status, GMP
Once Gaudium IVF IPO allotment is finalised, applicants can verify their allotment status online through the official websites of the BSE, NSE, or Bigshare Services, the registrar to the issue
SI Reporter New Delhi Gaudium IVF IPO allotment status: The basis of allotment of shares of the initial public offering (IPO) of
Gaudium IVF & Women Health is expected to be finalised today, February 25, 2026, following a decent investor interest that saw the issue subscribed 5.66 times, according to data available on the NSE.
The In Vitro Fertilization (IVF) treatments provider company’s ₹165-crore maiden offering witnessed a tepid start, reflecting cautious investor sentiment initially. However, demand surged sharply on the final day of bidding, led by non-institutional investors (NIIs).
NIIs bid for 18.23 times the shares reserved for their quota, and retail investors overbooked their category by 5.88 times. The qualified institutional buyers (QIBs), however, showed the lowest interest and only booked 93 per cent of the reserved quota.
Here's how to check Gaudium IVF IPO allotment status
Once the allotment is finalised, applicants can verify their allotment status online through the official websites of the BSE, NSE, or Bigshare Services, the registrar to the issue.
Direct links to check Gaudium IVF IPO allotment status online
Alternatively, investors can use the following direct links to check the Gaudium IVF IPO allotment status:
Gaudium IVF IPO grey market premium (GMP), listing date
Even as the allotment process for Gaudium IVF IPO shares is underway, the company’s unlisted shares are trading flat at around ₹79 per share (upper end of the IPO price) in the grey market, revealed the sources tracking unofficial market activities. Thus, the grey market premium (GMP) of Gaudium IVF IPO remains Nil on Wednesday.
The IVF treatments provider’s shares are slated to list on the BSE and NSE on Friday, February 27, 2026. Based on current grey market trends, the stock is expected to make a subdued debut, though analysts caution that the grey market premium (GMP) is an unofficial and speculative indicator and should not be viewed as a reliable measure of listing performance.